GHK-Cu in Sephora skincare: what the peptide science actually shows

What did @estheticswithari actually say?

The creator, a self-described 45-year-old esthetician, ran through a list of Sephora products and assigned them ratings like "15 out of 10" and "14 out of 10," which is a fun rhetorical move but tells you nothing clinically useful. The specific claims worth scrutinizing: resveratrol "rebuilds elasticity" so "cheeks and jawline tighten up," peptides "signal collagen production" around the eyes so "bags lift," and a Korean formula containing NAD+, niacinamide, peptides, and hyaluronic acid delivers "glass skin" through cellular repair. She also pushed viewers off-platform to Amazon for a cheaper version of that last product, which is worth noting for anyone worried about counterfeit cosmetics.

The core argument is that these over-the-counter topicals can produce structural changes in aging skin. That's a bold claim. Some of it has partial support. Some of it does not.

Does the science back this up?

Partially, and it depends heavily on which ingredient you're asking about. Peptides are probably the most defensible piece of this. Signal peptides like Matrixyl (palmitoyl pentapeptide-4) have shown modest but real effects on collagen synthesis in controlled studies. Gorouhi and Maibach (2009, Dermatology) reviewed peptide evidence and found certain signal peptides produced measurable improvements in wrinkle depth, though effect sizes were modest. That supports the Paula's Choice eye gel claim at least directionally.

Resveratrol is shakier. Most of the compelling mechanistic data comes from in vitro or animal studies. Human topical trials are limited and often industry-funded. The claim that it "rebuilds elasticity" to tighten a jawline is a significant overstatement of available evidence. A Cochrane-adjacent review would not be kind to that sentence.

NAD+ topically is genuinely interesting but early. Cellular NAD+ depletion is real and well-documented (Verdin, 2015, Science), but whether topical NAD+ precursors penetrate adequately to drive meaningful intracellular replenishment in skin is not settled. The hype is running well ahead of the evidence here.

What did they get wrong (or right)?

She got the peptide mechanism directionally right. Saying peptides "signal collagen production" is a reasonable plain-language description of how signal peptides work, and it's more accurate than most TikTok skincare content manages. Credit where it's due.

She got resveratrol wrong. "Rebuilds elasticity" so your "jawline tightens" is a structural claim that topical resveratrol has not earned in peer-reviewed human trials. Baxter et al. (2008, Journal of Drugs in Dermatology) showed some antioxidant benefit but nothing close to structural tightening.

The NAD+ claim is neither wrong nor right yet. It's premature. Presenting it as an established skin repair mechanism in a consumer product is getting ahead of the science.

The biggest problem: framing over-the-counter cosmetics as producing "lifted" cheeks and a "defined jawline" crosses from cosmetic claim territory into quasi-medical territory. Cosmetics by regulatory definition cannot structurally alter tissue. If a product actually did that, it would be classified as a drug. She's describing drug-level outcomes for cosmetic-category products.

What should you actually know?

If you're over 40 and serious about topical skincare, the ingredient evidence hierarchy looks roughly like this: retinoids (strongest long-term evidence for collagen remodeling), then sunscreen (non-negotiable), then certain peptides, then niacinamide, then antioxidants like vitamin C, then resveratrol and NAD+ precursors at the speculative end. The Dr. Dennis Gross peel recommendation is actually defensible. Alpha hydroxy acids do accelerate cell turnover and have solid evidence behind them (Bernstein et al., 2001, Dermatologic Surgery).

The Amazon redirect is a real concern. Sephora products purchased through unauthorized third-party Amazon sellers have documented issues with counterfeiting and improper storage. If product integrity matters to you, that shortcut has real risk.

Nothing in this video should be confused with peptide therapy as practiced in clinical or telehealth settings. Topical GHK-Cu in a cosmetic serum and injectable or systemic peptide protocols are entirely different categories with different evidence bases, different regulatory frameworks, and different risk profiles. Conflating them would be a mistake.